Fed. Circ. Revives Galderma's Patents On Rosacea Drug

Law360, New York (August 7, 2013, 5:48 PM EDT) -- The Federal Circuit on Wednesday vacated a district court's finding that two patents held by Galderma Laboratories Inc. for rosacea drug Oracea were invalid, ruling that the district judge did not adequately examine certain claims in light of prior art presented by generics manufacturer Mylan Pharmaceuticals Inc.

The three-judge panel said the district took too narrow a view in invalidating U.S. Patent Numbers  5,789,395 and  5,919,775, known as the Amin patents, which cover the use of certain antibiotics known as tetracyclines to inhibit nitrus oxide production...
To view the full article, register now.